International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 625-632 doi: 10.5281/zenodo.16879981
Original Article
Early Recurrence in Case of Squamous Cell Carcinoma Arising from Teratoma Post-Surgery and Adjuvant Chemotherapy: Two Case Reports and Literature Review
Published
Aug. 14, 2025
Abstract

Background: Malignant transformation in mature cystic teratoma (MCT) is a rare phenomenon, with squamous cell carcinoma (SCC) being the most frequent histologic subtype. Its diagnosis remains challenging due to nonspecific clinical and radiological findings, and the prognosis is generally poor.

Aim and Objective: To study the early recurrence in case of squamous cell carcinoma arising from teratoma post-surgery and adjuvant chemotherapy: two case reports and literature review.

Case Summary: We present two cases—one ovarian and one extra-gonadal teratoma—with histologically confirmed SCC, both managed with surgery followed by adjuvant Paclitaxel-Carboplatin chemotherapy. Despite this standard management, both cases showed early locoregional recurrence within weeks of treatment completion, highlighting the aggressive course of such malignancies.

Conclusion: These reports underscore the importance of early suspicion, aggressive surgical intervention, and the need for a more tailored adjuvant treatment strategy in SCC arising from teratomas. Further studies are warranted to identify prognostic biomarkers and optimal post-operative management.

 

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1425 Views
21 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved